Bristol-Myers Squibb Company (BMY)
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on a high yield can be dangerous because if it ends up getting cut, you could lose all or most of the dividend income, and the stock may crash in the process as dividend investors could look elsewhere for a high payout.
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo for resectable non-small cell lung cancer.
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Beat the S&P 500 With This Cash-Gushing Dividend Stock
Investors seeking relief from stock market volatility should take a closer look at Bristol Myers Squibb (BMY 1.77%). At the time of writing, shares of the healthcare giant have climbed 4% year to date -- a notable outlier amid the broader stock market sell-off, with the S&P 500 index currently down nearly 10% from its peak.
3 Deeply Discounted Dividend Stocks to Buy Today
Want to buy a good dividend stock and secure a great price in the process? I have a list of three stocks that can help you diversify your portfolio, allow you to earn above-average dividends, and score some potential bargains in the process.
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.
Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold
BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to value/ defensive stocks. This is significantly aided by the double beat FQ4'24 performance and the decent FY2025 guidance, as the management drives renewed growth through new portfolios and M&A activities. Despite the higher net debts on balance sheet, we believe that BMY's dividends remain safe as observed in the richer cash flows and recent payout raise.
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy
Merck and Bristol-Myers Squibb occupy leading positions in the cancer therapy market. Each of them has advantages, as well as dark spots in the portfolio of medications relative to the comparator. In this article, dear Seeking Alpha readers, you will learn whether Merck or Bristol-Myers Squibb is a more promising stock in the long term.
BofA Securities Says No Rate Cuts in 2025 or 2026: Grab These High-Yield Dividend Blue Chips Now
Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciation has contributed 68%.
Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note
Bristol Myers Squibb (BMY) reachead $60.08 at the closing of the latest trading day, reflecting a +0.3% change compared to its last close.
10 Undervalued Dividend Growth Stocks: March 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. I use two valuation screens, one based on my fair value estimate, and another comparing each stock's forward dividend yield with its 5-year average dividend yield. To rank stocks, I do a quality assessment and sort candidates by quality scores, breaking ties with additional metrics.
Bristol-Myers Squibb: Why I'm Still Bullish
I reiterate my "Buy" rating on Bristol-Myers Squibb due to its undervaluation, strong growth portfolio, and significant cost-saving initiatives. BMY's drug portfolio expansion and strategic productivity initiatives are expected to sustain high EBITDA margins and drive future top-line growth. Despite legacy drug challenges, BMY's growth portfolio shows robust revenue acceleration, with a projected fair value per share of $70.35, offering a 17.25% upside.
